Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
51 /100
HIGH RISK
Score updated Aug 28, 2026

GALT — Galectin Therapeutics Inc. Dilution Risk Tracker

Track GALT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GALT — Get alerts when the score changes →

As of August 28, 2026, Galectin Therapeutics Inc. (GALT) has a DilutionWatch DilutionScore of 51/100, rated HIGH dilution risk. Galectin Therapeutics Inc. has a market capitalization of $165.96M, 100.85M shares outstanding, 1 institutional holders tracked. Stored dilution-related fields include 500.0K outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
85
📊 Float Risk
45
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

Watch
Minor dilution signals detected
model est. 22%
💰 Capital Raise model 35%
• Low cash runway: 5 months remaining
🔄 Reverse Split model est. 15%
• Only 5 months cash — financial pressure
🔔 Track GALT — Get forecast alerts →

Market Data

Market Cap$165.96M
Shares Outstanding100.85M
Float47.19M
Cash$13.27M
Debt$138.70M
Short InterestN/A

Institutional Holdings

1 institutional holders · 12.4K shares
#1 49 WEALTH MANAGEMENT, LLC 12.4K shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest8.70M
Days to Cover23.6
% of Float18.4%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2021-04-16
Form 4 INSIDER TRANSACTION 2026-07-31
Form 4 INSIDER TRANSACTION 2026-07-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual GALT Dilution Snapshot

Galectin Therapeutics Inc. (GALT) has a DilutionScore of 51/100, rated High dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track GALT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking GALT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for GALT
GALT FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.